(e,e,e,e)-squalene

(e,e,e,e)-squalene is a lipid of Fatty Acyls (FA) class. (e,e,e,e)-squalene is associated with abnormalities such as Hypercholesterolemia and Cataract. The involved functions are known as Process, metaplastic cell transformation, Protein Overexpression, Anabolism and Biosynthetic Pathways. (e,e,e,e)-squalene often locates in Membrane, Protoplasm, Plasma membrane, Tissue membrane and Back. The associated genes with (e,e,e,e)-squalene are Genome, IMPACT gene, GAPDH gene, GTF2I gene and Chromatin. The related lipids are Membrane Lipids, cycloartenol, Sterols, Fatty Acids and Nonesterified Fatty Acids.

Cross Reference

Introduction

To understand associated biological information of (e,e,e,e)-squalene, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with (e,e,e,e)-squalene?

(e,e,e,e)-squalene is suspected in Hypercholesterolemia, Cataract and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with (e,e,e,e)-squalene

MeSH term MeSH ID Detail
Pain D010146 64 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Parkinson Disease D010300 53 associated lipids
Precancerous Conditions D011230 48 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Psoriasis D011565 47 associated lipids
Metabolism, Inborn Errors D008661 46 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Leukemia P388 D007941 43 associated lipids
Per page 10 20 50 100 | Total 84

PubChem Associated disorders and diseases

What pathways are associated with (e,e,e,e)-squalene

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with (e,e,e,e)-squalene?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with (e,e,e,e)-squalene?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with (e,e,e,e)-squalene

Download all related citations
Per page 10 20 50 100 | Total 1766
Authors Title Published Journal PubMed Link
Ott G et al. Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. 1995 Vaccine pmid:8578842
Barnett SW et al. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. 1997 Vaccine pmid:9234536
Hilgers LA et al. A novel non-mineral oil-based adjuvant. I. Efficacy of a synthetic sulfolipopolysaccharide in a squalane-in-water emulsion in laboratory animals. 1994 Vaccine pmid:8085385
Hilgers LA et al. A novel non-mineral oil-based adjuvant. II. Efficacy of a synthetic sulfolipopolysaccharide in a squalane-in-water emulsion in pigs. 1994 Vaccine pmid:8085386
Byars NE et al. Vaccinating guinea pigs with recombinant glycoprotein D of herpes simplex virus in an efficacious adjuvant formulation elicits protection against vaginal infection. 1994 Vaccine pmid:8165851
Heineman TC et al. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. 1999 Vaccine pmid:10438046
De Donato S et al. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. 1999 Vaccine pmid:10462245
Black S et al. Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis. 2010 Vaccine pmid:20813217
Decaro N et al. Immunogenicity and protective efficacy in dogs of an MF59â„¢-adjuvanted vaccine against recombinant canine/porcine coronavirus. 2011 Vaccine pmid:21272607
Calabro S et al. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. 2011 Vaccine pmid:21215831
Pietrella D et al. A beta-glucan-conjugate vaccine and anti-beta-glucan antibodies are effective against murine vaginal candidiasis as assessed by a novel in vivo imaging technique. 2010 Vaccine pmid:20038431
Camilloni B et al. An influenza B outbreak during the 2007/2008 winter among appropriately immunized elderly people living in a nursing home. 2010 Vaccine pmid:20846530
Radosević K et al. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants. 2008 Vaccine pmid:18514980
de Bruijn I et al. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. 2007 Vaccine pmid:18063446
Puig-Barberà J et al. Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age. 2004 Vaccine pmid:15530669
Schultze V et al. Safety of MF59 adjuvant. 2008 Vaccine pmid:18462843
Iorio AM et al. Influenza viruses and cross-reactivity in healthy adults: humoral and cellular immunity induced by seasonal 2007/2008 influenza vaccination against vaccine antigens and 2009 A(H1N1) pandemic influenza virus. 2012 Vaccine pmid:22245606
O'Hagan DT et al. The mechanism of action of MF59 - an innately attractive adjuvant formulation. 2012 Vaccine pmid:22682289
Tetsutani K and Ishii KJ Adjuvants in influenza vaccines. 2012 Vaccine pmid:23084848
Poder A et al. An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age. 2014 Vaccine pmid:24252703